



Recommendations for the prioritization of ID Now^{MD} point of care COVID-19 analysis – Nunavik region

By Simon Riendeau MD and Véronique Morin, MD

April 5th, 2022

CONTEXT

The use and volume of COVID-19 screening analyzes on the ID Now^{MD} platform in Nunavik communities depend on the resources (human and material) available in the clinical teams (number of platforms deployed, trained staff available, dedicated resources, etc.) and therefore remain at the discretion of these teams.

The recommendations below describe how to handle requests when they exceed availability.

Modifications are made to reflect changes in epidemiology, changes in the management of cases and contacts, and the advent of pharmacological treatments for COVID-19.

PRIORITIZATION

#1 Patient with a clinical indication to receive pharmacological treatment for COVID-19¹

#2 Critical worker identified as contact and/or symptomatic, who remains at work

#3 Person at risk of exposing a vulnerable environment (inmate, patient or employee in healthcare setting, medevacs, etc.)

#4 Symptomatic patient in a vulnerable situation (other than prioritization #1)

#5 Symptomatic patient

¹ An ID Now[®] or PCR test is recommended for anyone who may benefit from pharmacological treatment for COVID-19. However, if a rapid antigenic test has been done and it is positive, it is not necessary to proceed to the ID Now[®] or the PCR; if it is negative, it is recommended to complete with an ID Now[®] or a PCR.